MARKET

NUVL

NUVL

Nuvalent, Inc.
NASDAQ
123.97
+0.03
+0.02%
Opening 12:11 07/14 EDT
OPEN
123.96
PREV CLOSE
123.94
HIGH
123.98
LOW
123.95
VOLUME
568.63K
TURNOVER
--
52 WEEK HIGH
123.98
52 WEEK LOW
71.13
MARKET CAP
9.81B
P/E (TTM)
-20.4799
1D
5D
1M
3M
1Y
5Y
1D
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Barchart · 1d ago
Weekly Report: what happened at NUVL last week (0706-0710)?
Weekly Report · 1d ago
BUZZ-Biopharma dealmaking on way to record year, says HSBC
Reuters · 4d ago
Biotech rally rests on fundamentals, M&A appetite, says ROTY's Faison
Seeking Alpha · 5d ago
Nuvalent CEO James Richard Porter disposes of 30,000 common shares for $3.71 million
PUBT · 5d ago
Nuvalent CFO Alexandra Balcom disposes of 11,430 common shares worth $1.41 million
PUBT · 07/06 20:31
Weekly Report: what happened at NUVL last week (0629-0703)?
Weekly Report · 07/06 09:15
Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)
TipRanks · 07/06 06:40
More
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Webull offers Nuvalent, Inc stock information, including NASDAQ: NUVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVL stock methods without spending real money on the virtual paper trading platform.